 |
|
|
| |
ICAAC 41st Interscience Conference on Antimicrobial Agents and Chemotherapy
Chicago, Illinois, December 16-19 |
| |
| |
- Immunology Overview - The importance of immunology Written for NATAP by Michael Norton, PA-C, Boriken Health Clinic, NYC - Jan 30, 2002
- FOCUS Study: 24-week interim analysis - Jan 18, 2002
- Pancreatitis in HIV - Jan 14, 2002
- Abacavir Resistance - Jan 14, 2002
- Bone Abnormalities at ICAAC: Osteoporosis, Osteonecrosis Written for NATAP by Michael Norton, PA-C, Boriken Health Clinic, NYC - Jan 10, 2002
- Hepatitis Report from ICAAC Nancy Shulman, MD, Stanford University - Jan 07, 2002
- Amprenavir "908" prodrug once & twice a day with Efavirenz. - Jan 07, 2002
- HEPATITIS ABSTRACTS PRESENTED AT 41ST ANNUAL INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPEUTICS Written by Andrew Talal, MD, Cornell-NY Hospital, NYC - Jan 04, 2002
- Selected review of HIV resistance presented at the 41st ICAAC Andrew R. Zolopa, MD Stanford University - Jan 04, 2002
- Entry Inhibitors
Written by: Michael Norton, PA, Boriken Family Health Clinic - Jan 02, 2002
- How Low Does Viral Load Have To Be? - Jan 02, 2002
- Therapy Interruptions in HIV
Written for NATAP by Michael Norton, PA, Boriken Family Health Clinic, NYC
Editorial contribution by Jules Levin - Jan 02, 2002
- DDI EC and Food and Timing of Dosing - Jan 02, 2002
- TRIZAL: a randomized comparative study of switch to Trixivir compared to HAART in patients successfully treated with HAART - Jan 02, 2002
- Pharmacogenetics of Antiretrovirals - Jan 02, 2002
- Therapeutic Vaccinations in HIV
Written by Michael Norton, PA, Boriken Family Health Clinic, NYC - Jan 02, 2002
- New HIV drugs, resistance, pharmacogenomics
Written by Mike Youle, Director of HIV at Royal Free Hospital, UK, London - Dec 27, 2001
- Drug Interactions and Pharmacokinetics of Antiretrovirals (part 1) Written by Stephen Piscitelli, Pharm.D. Associate Director, Clinical Pharmacology Tibotec-Virco - Dec 27, 2001
- Pharmacokinetic Issues of Antiretrovirals (part 2) Written by Stephen Piscitelli, Pharm.D. Associate Director, Clinical Pharmacology Tibotec-Virco - Dec 27, 2001
- Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptide Protease Inhibitor in PI-Failure Patients Written by Jules Levin - Dec 27, 2001
- Anitiretroviral Agents: adherence, PK Written by Scott Penzak, PharmD, National Institutes of Health - Dec 27, 2001
- Antiretroviral Therapy: Part 2.- FTC, Interferon, TMC-114 (new PI) Reported for NATAP by Grame Moyle, MD, Ass. Dir. of HIV Research at Chelsea &
Westminster Hospital, UK, London - Dec 27, 2001
- Kaletra and Amprenavir Interaction Two Reports: Impact of ABT 378/r (Kaletra) on the amprenavir (APV) plasma concentrations in HIV-experienced patients treated by the association APV-ABT 378/r by Scott Penzak, PharmD, NIH - and- APV + Kaletra: Is there an interaction here? by Written by Steve Piscatelli, PharmD, Tibotec-Virco - Dec 27, 2001
- ddI-Tenofovir interaction; ddI-Ribavirin-Interferon interaction; 3TC-ribavirin interaction; elevated glucose & diabetes in HCV/HIV coinfected patients Written for NATAP by Stephen Piscitelli, Pharm.D., Associate Director, Clinical Pharmacology, Tibotec-Virco and Jules Levin, NATAP - Dec 27, 2001
- The Prevalence of Antiretroviral Drug Resistance in the US - Dec 27, 2001
- Antiviral PK and Drug-Drug Interactions, Report #1 Reported for NATAP by Scott Penzak, PhD, National Institutes of Health (NIH) - Dec 21, 2001
- NATAP ICAAC 2001 Antiretroviral therapy, Part 1 Dr Graeme Moyle, Chelsea and Westminster Hospital, London, UK. - Dec 21, 2001
- Solid Organ Transplantation in Patients with Human Immunodeficiency Syndrome: a Successful Case Series. - Dec 21, 2001
- TMC125 is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in Antiretroviral Therapy (ART)-Naive, HIV-1 Infected Subjects. - Dec 21, 2001
- BMS-008 Comparative Results of Atazanavir vs Nelfinavir in Combination With d4T (Stavudine) and 3TC (Lamivudine) in treatment-Naive, HIV-Infected Patients - Dec 21, 2001
- Tenofovir 24 week Interim Analysis Phase III Trial in Treatment-Experienced Patients - Dec 19, 2001
- Once-Daily Atazanavir plus Saquinavir Favorably Affects Total Cholesterol and Fasting Triglycerides in patients Failing Prior PI Therapy Study BMS-009, week 24) - Dec 19, 2001
- Amprenavir (APV) Plasma and Intracellular Concentrations When Co-Administered with Ritonavir (RTV) in Twice and Once Daily Regimens in HIV-Infected Patients - Dec 17, 2001
- Evaluation of Two doses of Peginterferon Alfa-2a (40KD) (Pegasys) for the Treatment of Chronic Hepatitis C - Dec 17, 2001
|
|
| |
|
|
|
|
|
